Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China.
The last earnings update was 65 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cellular Biomedicine Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Cellular Biomedicine Group's
is considered below, and whether this is a fair price.
Price based on past earnings
Cellular Biomedicine Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
Cellular Biomedicine Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
Cellular Biomedicine Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cellular Biomedicine Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Cellular Biomedicine Group
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cellular Biomedicine Group's finances.
The net worth of a company is the difference between its assets and liabilities.
Cellular Biomedicine Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Cellular Biomedicine Group's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Cellular Biomedicine Group's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Cellular Biomedicine Group has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Bizuo Liu, also known as Tony, has been Chief Executive Officer of Cellular Biomedicine Group Inc. since February 7, 2016 and serves as its Chief Financial Officer and served as its Secretary since January 03, 2014. Mr. Liu has been Corporate Vice President at Alibaba Group since January 2013 and is responsible for its overseas investments. Since joining Alibaba in 2009, he has held various positions including Corporate Vice President at B2B corporate investment, corporate finance and General Manager for a global ecommerce platform. He served as the Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider from July 2011 to December 2012. Mr. Liu spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He served as the General Manager of Corporate Strategy looking after Microsoft's China investment strategy and corporate strategic planning process. He was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process and showcased Microsoft's best practices to many Fortune 500 companies in the U.S. He has been a Director of Cellular Biomedicine Group Inc. since February 2013. He obtained his Washington State CPA certificate in 1992. Mr. Liu earned a B.S. degree in Physics from Suzhou University, Suzhou, PRC and has completed MBA/MIS course work at Seattle Pacific University.
Tony 's compensation has been consistent with company performance over the past year.
Tony 's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
Cellular Biomedicine Group
management team in years:
The average tenure for the Cellular Biomedicine Group management team is less than 2 years, this suggests a new team.
CEO, CFO & Director
Chief Scientific Officer
Chief Legal Officer
Chief Production Officer
Head of Strategy & Investor Relations
Director of Corporate Communications
Zhong Chen Kou
Chief Scientist of Immunology
Head of Early Diagnosis & Intervention
Board of Directors Tenure
Average tenure and age of the
Cellular Biomedicine Group
board of directors in years:
The tenure for the Cellular Biomedicine Group board of directors is about average.
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.